News and Announcements
Total Blood Profile has had a third patent granted for our rapid diagnostic tests in the US
- Published December 16, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Key Takeaways:
The new patent covers the rapid detection of diseases caused by parasites such as malaria and Lyme disease. This comes after a recent patent was granted for the diagnosis of blood borne diseases using infrared spectroscopy.
Total Blood Profile now has three patents granted in the US with many other patents pending in other key markets such as India, China, Europe, Japan, Australia and Canada. These patents cover the use of infrared spectroscopy to rapidly and easily diagnose a range of the world’s most devastating diseases.
About Total Blood Profile
Total Blood Profile is commercialising a revolutionary new blood test that addresses some of the world’s biggest unmet clinical needs such as; sepsis, hepatitis, malaria and the rapid detection of antibiotic-resistant ‘superbugs’. Our patented diagnostic platform was developed by the Monash University Centre for Biospectroscopy. It is faster, easier and is more cost-effective than current technologies and delivers rapid, quantitative detection of a wide range of pathogens and biomarkers in bodily fluids.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
